Protalix BioTherapeutics Overview
Valuation check: PLX's P/E ratio is 9.88, below the Healthcare sector average of 26.85.
Get informed when a big investor buys or sells
+ Follow9.88
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, PLX shows a P/E ratio of 9.88. That is below the Healthcare sector average of 26.85. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 26.85. Protalix BioTherapeutics is at 9.88, which is lower that average. That is roughly 63.2% below the sector mean. Use the comparison chart on this page to see how PLX stacks up against individual peers as well.
Investors watch PLX's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Protalix BioTherapeutics's latest reading is 9.88. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Protalix BioTherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently 9.88) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 26.85, while PLX is at 9.88. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
